Novo Nordisk Inc. provided funding support for the Elivate: Creating change through liver education metabolic dysfunction-associated steato-hepatitis (MASH) curriculum. Elivate was developed by Novo Nordisk Inc., in collaboration with a steering committee of liver health experts, to address gaps in MASH education and support healthcare professionals with diagnosis and management for people with MASH. The goal of Elivate is to present a complete, accurate, non-promotional, and evidence-based picture of the current state of MASH.
Elivate MASH Education Curriculum
Modules are currently in development and coming soon. Speak to your medical representative to stay informed about the Elivate Curriculum.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
